Form 4: Mineralys Therapeutics CMO Exercises Options and Sells Shares Under Pre-Arranged Plan

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, executed stock option exercises and subsequent share sales on July 14, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Chief Medical Officer David Malcom Rodman engaged in transactions involving Mineralys Therapeutics, Inc. common stock.
• On July 14, 2025, Rodman acquired 6,349 shares of common stock by exercising stock options at a price of $1.08 per share.
• Concurrently, on July 14, 2025, he sold 11,366 shares of common stock at a weighted-average price of $14.5943 per share, with individual sales ranging from $14.0700 to $14.7594.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on October 25, 2024.
• Following these transactions, Rodman beneficially owns 97,907 shares of common stock directly.
• The reported common stock balance includes 1,273 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.
• Rodman also holds 88,880 stock options, which vested 25% on July 12, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter, expiring on July 11, 2032.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (exercise and sell) under a pre-arranged plan, which is common and does not inherently indicate positive or negative sentiment about the company's future prospects.

Positives

• The exercise of stock options indicates a vesting event and conversion of options to shares, reflecting a component of executive compensation.
• The stock option exercise price of $1.08 is significantly lower than the sale price, indicating a profitable transaction for the insider.
• The transactions were conducted under a Rule 10b5-1 trading plan, which signifies pre-planned and automated sales, often reducing concerns about opportunistic insider trading.

Negatives

• The sale of 11,366 shares by a Chief Medical Officer reduces his direct common stock holdings.

Future Outlook

The remaining 88,880 stock options held by the Chief Medical Officer are scheduled to vest in 36 substantially equal monthly installments following July 12, 2022, with an expiration date of July 11, 2032.

Industry Context

This Form 4 filing represents a routine insider transaction for a biotechnology company, where executives often exercise stock options and sell shares for liquidity or portfolio diversification, particularly when such transactions are pre-arranged under a Rule 10b5-1 plan.

Comparison to Industry Standards

• Insider transactions like these are common across the biotechnology and pharmaceutical sectors, where executive compensation often includes significant equity components such as stock options.
• The use of a Rule 10b5-1 plan aligns with best practices for corporate insiders to manage their equity holdings in a pre-scheduled and transparent manner, similar to practices observed at companies like Pfizer, Moderna, or Johnson & Johnson, where executives routinely manage their equity compensation.

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Medical Officer could be perceived as a slight reduction in insider alignment, though the pre-arranged nature via a 10b5-1 plan mitigates this concern. The transaction provides liquidity to the executive.

Next Steps

• Continued vesting of the remaining 88,880 stock options in 36 substantially equal monthly installments.

Key Dates

Keywords

Mineralys Therapeutics, MLYS, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Chief Medical Officer, David Malcom Rodman, Equity Transaction, Biotechnology, Pharmaceuticals